Many Unanswered Questions About Risks for Contralateral Breast Cancer Led to CARRIERS Study, Says Expert

Video

An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.

What role genetic germline pathogenic variants play in the risk for developing contralateral breast cancer—a second cancer following the first invasive breast cancer—is an important question to answer, according to Siddhartha Yadav, MD, MBBS, a medical oncologist and assistant professor of Medicine and Oncology at Mayo Clinic in Rochester, Minnesota.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Yadav about the rationale for performing the population-based case-controlled CARRIERS study assessing germline pathogenic variants and other factors as risks for contralateral breast cancer.

According to Yadav, there was not a well-defined understanding of how germline mutations in ATM, CHEK2, and PALB2 affected the risk for contralateral breast cancer, which investigators of the study aimed to address. He also said that investigating other potential factors such as menopausal status was important in the context of germline mutations.

Transcript:

Our understanding of breast cancer risk in germline mutation carriers is primarily really limited to BRCA1 or BRCA2 mutation carriers. And for some of these moderate-risk genes, such as CHEK2, ATM, or PALB2, we don't really know what the contralateral breast cancer risk is. In addition, a lot of different other factors such as menopausal status as a diagnosis have not been investigated comprehensively in the context of contralateral breast cancer risk in germline mutation carriers. So, we wanted to create an unbiased population-based study to look at contralateral breast cancer to answer some of these questions, including [those] for moderate-risk genes, [and] also for BRCA1/2. Answering these questions in a population-based setting was important.

Reference

Yadav S, Boddicker NJ, Na J, et al. Population-based estimates of contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX. Abstract GS4-04.

Related Videos
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content